Anti-cryptosporidium parvum preparations
AssigneesThe Arizona Board of Regents Acting on Behalf of the University of Arizona, North Carolina State University
InventorsMichael W. Riggs, Lance E. Perryman
Life of this patent
Estimating the term…
Loading patent…
AssigneesThe Arizona Board of Regents Acting on Behalf of the University of Arizona, North Carolina State University
InventorsMichael W. Riggs, Lance E. Perryman
Estimating the term…
Compositions and methods useful for conferring passive or active immunity to the parasite, C. parvum. A high molecular weight glycoprotein antigen isolated from C. parvum, capable of binding the mAb 3E2, was shown to harbor an epitope critical for triggering the neutralizing CSP-like reaction in the parasite. Antibodies targeted against the critical epitope were shown to possess neutralizing activity, and could be combined with other anti-C. parvum monoclonal antibodies and administered to an animal to confer passive immunity. Immunogenic compositions including the purified antigen are disclosed for use in stimulating an active immune response against C. parvum.
An isolated antigen of Cryptosporidium parvum comprising a glycoprotein of approximately 1,400 kDa, as measured by sodium dodecyl sulfate polyacrylamide gel electrophoresis, said antigen having disposed thereon an epitope specifically recognizable by monoclonal antibody 3E2, secreted by a hybridoma deposited as accession number ATCC HB 12075, wherein the antigen is present in unisolated form in dense granules in sporozoites.
An immunogenic composition comprising a substantially purified Cryptosporidium parvum antigen comprising a glycoprotein of approximately 1,400 kDa, as measured by sodium dodecyl sulfate polyacrylamide gel electrophoresis, wherein said antigen is specifically recognizable by monoclonal antibody 3E2, secreted by a hybridoma deposited as accession number ATCC HB 12075, in a pharmaceutically acceptable carrier.
A method of stimulating an anti-Cryptosporidium parvum immune response in a mammal comprising administering to the mammal an immunogenic composition comprising a substantially purified Cryptosporidium parvum antigen specifically recognizable by monoclonal antibody 3E2, secreted by a hybridoma deposited as accession number ATCC HB 12075, in a pharmaceutically acceptable carrier, wherein said antigen is a glycoprotein of approximately 1,400 kDa, as measured by sodium dodecyl sulfate polyacrylamide gel electrophoresis.
Dependencies are inferred from the claim text.